argenx SE (ARGNF)
OTCMKTS · Delayed Price · Currency is USD
800.00
0.00 (0.00%)
At close: Sep 10, 2025
argenx SE Revenue
argenx SE had revenue of $967.19M in the quarter ending June 30, 2025, with 97.62% growth. This brings the company's revenue in the last twelve months to $3.12B, up 88.04% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.22% growth.
Revenue (ttm)
3.12B
Revenue Growth
+88.04%
P/S Ratio
14.81
Revenue / Employee
1.95M
Employees
1,599
Market Cap
46.22B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.25B | 979.61M | 77.22% |
Dec 31, 2023 | 1.27B | 827.58M | 187.66% |
Dec 31, 2022 | 441.01M | -87.25M | -16.52% |
Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Global Cord Blood | 196.10M |
argenx SE News
- 2 days ago - $1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today - Benzinga
- 4 days ago - Is argenx Gaining or Losing Market Support? - Benzinga
- 4 days ago - Argenx SE (ARGX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - B of A Securities Raises Price Target on ARGX to $887 | ARGX Stock News - GuruFocus
- 16 days ago - argenx to Present at Upcoming Investor Conferences - GlobeNewsWire
- 17 days ago - Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded - Investor's Business Daily
- 17 days ago - Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win - Benzinga
- 17 days ago - Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win - Benzinga